MAPT and early-onset autosomal dominant Alzheimer disease: In transgenic mouse models of Alzheimer’s disease, liraglutide improves memory, prevents synaptic loss, reduces β-amyloid and tau aggregation, reduces neuroinflammation and oxidative stress, restores protein kinase A and phosphoinositide 3‐kinase/protein kinase B signaling and improves insulin signaling2–4.